OM Pharma

OM Pharma
Company typeSociété Anonyme
IndustryBiopharmaceutical
FoundedBarcelona, (1930)
HeadquartersGeneva, Switzerland
Area served
Worldwide
Key people
  • Roch Ogier (CEO)
Products
OM-89
OwnerEtienne Jornod (Executive Chairman & Co‑Owner)
Websitewww.ompharma.com

OM Pharma is a Swiss multinational biopharmaceutical company headquartered in Geneva.

In 2020, the company became part of Optimus Holding, led by Etienne Jornod.[1]In 2021, OM Pharma received the Geneva Economy Award.[2] OM Pharma is the only pharmaceutical company that manufactures in Geneva.

The company specializes in developing and commercializing bacterial lysate-based products designed to help prevent respiratory and urinary tract infections by enhancing the immune system. Its research pipeline includes future applications of lysates.[3]

History

Origins

OM Pharma traces its origins to Barcelona in 1930, when French pharmacist Jean-René Ricard founded a small pharmaceutical laboratory focused on biologically derived medicines. The outbreak of the Spanish Civil War in 1936 forced the Ricard family to leave Spain, and in 1937 the company relocated to Geneva, Switzerland. At that point the business was renamed OM Pharma, with OM standing for the Latin expression Omnia Medicamenta, meaning all medicines.

Integration into CSL Vifor/Galenica

In 1970, OM Pharma relocated its main operations to Meyrin, where the company continues to operate. In 2009, it was acquired by Galenica, a part of the Vifor Pharma Group.[4][5][6]

Acquisition by Optimus Holding

In 2020, OM Pharma was acquired by Optimus Holding, led by former Vifor Pharma Executive Chairman Etienne Jornod with a consortium of inverstors.[7] As part of the transaction, Optimus Holding committed to investing over CHF 250 million to enhance the company’s manufacturing and research capabilities.[8] Since 2024, Roch Ogier has served as the company’s CEO.[9]

Structure and subsidiaries

OM Pharma employs over 400 people, with its global headquarters and biotech campus located in Meyrin, Geneva, and an affiliate in Villars-sur-Glâne, Fribourg.[10]

The company also operates in Peru through an affiliate in Lima and maintains a sales force in Central America, covering Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica, Panama, and the Dominican Republic.[11][12]

Products

OM Pharma’s products include:

  • Broncho-Vaxom (OM-85) indicated for the prevention of recurrent respiratory tract infections.[13][14] With continued research on asthma prevention in high-risk infants[15]
  • Uro-Vaxom (OM-89) indicated for the prevention of recurrent urinary tract infections [16]
  • Doxium (calcium dobesilate) indicated in treatment of microangiopathies, signs of chronic venous insufficiencies in the lower limbs, diabetic retinopathy and hemorrhoidal syndrome[17][18]
  • Dicynone (etamsylate) indicated in the treatment of capillary hemorrhages [19]

References

  1. ^ "Etienne Jornod achète une deuxième fois OM Pharma à Genève - Le Temps" (in French). 18 September 2020. ISSN 1423-3967. Retrieved 30 October 2024.
  2. ^ "OM Pharma Wins Geneva Economy Award". PharmExec. 21 September 2021. Retrieved 13 November 2024.
  3. ^ Ogier, Roch; Kherad, Omar; Balavoine, Michael (22 January 2025). "Le travail de l'industrie pharmaceutique reste largement méconnu". Rev Med Suisse (in Swiss French). 902: 116–118.
  4. ^ "Galenica acquiert la société biotech OM Pharma - Le Temps" (in French). 8 September 2009. ISSN 1423-3967. Retrieved 1 November 2024.
  5. ^ "BioAlps | 20 years of innovation | OM Pharma". BioAlps. 20 October 2021. Retrieved 30 October 2024.
  6. ^ "économie - L'entreprise compte 65 % de frontaliers parmi ses 200 collaborateurs. OM Pharma, rescapée genevoise de la pharmaceutique, a 80 ans". www.ledauphine.com (in French). 9 November 2017. Retrieved 1 November 2024.
  7. ^ "Etienne Jornod, président d'OM Pharma à Genève: «Il ne faut pas baisser le prix des médicaments de façon linéaire» - Le Temps" (in French). 13 December 2024. ISSN 1423-3967. Retrieved 18 December 2024.
  8. ^ PricewaterhouseCoopers. "Vifor Pharma Group announces successful sale of OM Pharma to Optimus Holding Ltd". PwC. Retrieved 30 October 2024.
  9. ^ "La Gazette du Laboratoire – OM Pharma nomme Roch Ogier au poste de CEO". www.gazettelabo.fr. Retrieved 1 November 2024.
  10. ^ "Redevenue indépendante, OM Pharma vise les Etats-Unis - Le Temps" (in French). 13 December 2024. ISSN 1423-3967. Retrieved 18 December 2024.
  11. ^ "OM Pharma situa su filial peruana como hub regional para Latinoamérica". PMFarma. Retrieved 30 October 2024.
  12. ^ "Farmacéutica | OM Pharma sitúa hub regional en Perú, las razones detrás y negocios a la vista | ECONOMIA". Gestión (in Spanish). 3 May 2023. Retrieved 1 November 2024.
  13. ^ Yin, Ju; Xu, Baoping; Zeng, Xiantao; Shen, Kunling (1 January 2018). "Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis". International Immunopharmacology. 54: 198–209. doi:10.1016/j.intimp.2017.10.032. ISSN 1567-5769. PMID 29154122.
  14. ^ "OM85: could bacteria in a capsule protect us from coronavirus and other respiratory infections?". medicine.uq.edu.au. 11 June 2020. Retrieved 14 August 2025.
  15. ^ "(ORBEX) Randomized, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of Oral Bacterial Extract for the prevention of wheezing lower respiratory tract illness". airways.uahs.arizona.edu. Retrieved 14 August 2025.
  16. ^ Brodie, Andrew; El-Taji, Omar; Jour, Ibrahim; Foley, Charlotte; Hanbury, Damian (October 2020). "A Retrospective Study of Immunotherapy Treatment with Uro-Vaxom (OM-89®) for Prophylaxis of Recurrent Urinary Tract Infections". Current Urology. 14 (3): 130–134. doi:10.1159/000499248. ISSN 1661-7649. PMC 7659410. PMID 33224005.
  17. ^ Allain, Herv??; Ramelet, Albert A; Polard, Elisabeth; Bentu??-Ferrer, Dani??le (2004). "Safety of Calcium Dobesilate in Chronic Venous Disease, Diabetic Retinopathy and Haemorrhoids". Drug Safety. 27 (9): 649–660. doi:10.2165/00002018-200427090-00003. ISSN 0114-5916. PMID 15230646.
  18. ^ Liu, Jie; Li, Shulin; Sun, Dong (15 March 2019). "Calcium Dobesilate and Micro-vascular diseases". Life Sciences. 221: 348–353. doi:10.1016/j.lfs.2019.02.023. ISSN 1879-0631. PMID 30769115.
  19. ^ Garay, Ricardo P.; Chiavaroli, Carlo; Hannaert, Patrick (2006). "Therapeutic efficacy and mechanism of action of ethamsylate, a long-standing hemostatic agent". American Journal of Therapeutics. 13 (3): 236–247. doi:10.1097/01.mjt.0000158336.62740.54. ISSN 1075-2765. PMID 16772766.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.